Six Peptide Drug Development Signals R&D and CMC Teams Should Watch in 2026

1. U.S. compounding review puts evidence and API characterization in focus

On July 23 and 24, 2026, the U.S.

Food and Drug Administration convened its Pharmacy Compounding Advisory Committee to discuss seven groups of bulk drug substances nominated for possible inclusion on the Section 503A Bulks List.

The substances were BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax and Epitalon, including specified free-base and acetate forms.

This was not a marketing-authorization review.

FDA's briefing materials proposed that the evaluated forms should not be included on the 503A list, while explaining that advisory-committee recommendations are non-binding and that the agency's final determination is separate.

For peptide developers, the practical signal is the attention being given to human-exposure evidence, immunogenicity, aggregation, peptide-related impurities and API characterization.

A visible peptide name is not a substitute for a defensible identity, impurity and regulatory-status package.

2. Retatrutide moves triple-receptor agonism into pivotal development

Retatrutide is an investigational peptide designed to activate GIP, GLP-1 and glucagon receptors.

Lilly's TRIUMPH-1 Phase 3 trial randomized 2,339 participants with obesity or overweight, at least one weight-related comorbidity and no diabetes to retatrutide or placebo.

Under the sponsor-reported efficacy estimand at week 80, mean body-weight change was −19.0% with 4 mg, −25.9% with 9 mg and −28.3% with 12 mg, compared with −2.2% with placebo.

In the 12 mg group, 45.3% reached at least 30% body-weight reduction.

In a prespecified extension involving participants with a baseline BMI of at least 35 kg/m², the 12 mg group reached a mean reduction of 30.3% at week 104.

The extension was not a conventional long-term placebo comparison because the original placebo group transitioned to active treatment.

Lilly later announced positive topline results from TRIUMPH-2 and TRIUMPH-3 and stated that it planned a U.S. submission in 2027.

Retatrutide remained investigational as of this update.

A triple agonist requires receptor-specific potency, a justified activity balance, modified-residue control, degradation-pathway understanding, conjugate consistency and formulation stability.

3. CagriSema shows that combination architecture is also a CMC challenge

CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analogue, in a once-weekly fixed-dose product.

REDEFINE 1 was a 68-week Phase 3 trial involving 3,417 adults without diabetes who had obesity or overweight with at least one related complication.

Under the treatment-policy estimand, estimated mean body-weight change was −20.4% with CagriSema, −14.9% with semaglutide, −11.5% with cagrilintide and −3.0% with placebo.

An estimated 91.9% of the CagriSema group achieved at least 5% reduction.

For the 25% threshold, the peer-reviewed treatment-policy estimate was 34.7%; the often-cited 40.4% figure came from the trial-product estimand, which modeled the effect if participants remained on treatment.

Novo Nordisk submitted a U.S. application in December 2025 and reported that an FDA decision was anticipated in late 2026.

CagriSema remained investigational in the United States and European Union in the official status materials used for this update.

Its fixed-dose architecture creates questions about component ratio, co-formulation stability, degradation interactions, device compatibility, release methods and the ability to distinguish each active component and its related impurities.

4. Amylin analogues are expanding beyond the GLP-1-only model

Petrelintide is an investigational, long-acting human amylin analogue.

In an earlier 16-week multiple-ascending-dose study, the sponsor reported mean body-weight changes of −4.8%, −8.6% and −8.3% across three dose groups, compared with −1.7% for pooled placebo.

The study was small, with approximately 12 participants randomized per group, and should be interpreted as early-phase evidence.

The later ZUPREME-1 Phase 2 program enrolled 493 participants.

At week 42, the ADA 2026 presentation reported estimated mean reductions of up to 10.7%, compared with 1.7% for placebo under the efficacy estimand.

Most gastrointestinal events in the pooled petrelintide group were reported as mild, although the results remain investigational and sponsor-supported.

Combination development is continuing.

The currently registered program pairs petrelintide with Roche's incretin candidate enicepatide, formerly CT-388.

It should not be confused with CagriSema, the separate cagrilintide–semaglutide strategy.

5. Mazdutide demonstrates the importance of jurisdiction-specific status

Mazdutide is a dual glucagon and GLP-1 receptor agonist developed by Innovent under a China-focused license from Lilly.

China's NMPA approved it in June 2025 for chronic weight management in defined Chinese adults with obesity or overweight.

That approval is jurisdiction- and indication-specific; it does not establish approval or commercial eligibility elsewhere.

GLORY-1 randomized 610 adults in China to 4 mg mazdutide, 6 mg mazdutide or placebo.

Innovent's approval announcement reported week-48 efficacy-estimand changes of −12.0%, −14.8% and −0.5%, respectively.

In the 6 mg group, 82.8% achieved at least 5% body-weight reduction and 50.6% achieved at least 15%, compared with 11.5% and 2.1% for placebo.

The peer-reviewed treatment-policy analysis reported −14.01% for 6 mg and +0.30% for placebo, showing why estimands should accompany clinical percentages.

The wider signal is that China-origin peptide programs are producing pivotal data, approved products and lifecycle-development plans.

International development still requires market-specific regulatory strategy, product status, intellectual-property analysis, CMC comparability and supply-chain qualification.

6. AI is entering peptide design, but it does not replace experimental evidence

AI tools are increasingly applied to sequence generation, target binding, solubility, permeability, toxicity, hemolysis, half-life and other early developability questions.

A 2026 Nature Communications paper describing PeptiVerse, for example, evaluated prediction across canonical sequences and chemically modified peptides represented as SMILES.

These models can help teams rank candidates and prioritize experiments.

They do not independently establish biological activity, safety, manufacturability or clinical relevance.

Prediction quality is constrained by dataset coverage, assay comparability, chemical representation and the distance between a new candidate and the training data.

For CMC teams, an attractive generated sequence is only the beginning.

Synthesis feasibility, deletion sequences, epimerization, oxidation, aggregation, purification behavior, conjugation consistency, formulation stability and scalable analytical control still require experimental design–build–test cycles.

7. What these signals mean for peptide R&D and CMC teams

The 2026 peptide landscape is diversifying across triple agonists, fixed-dose combinations, amylin analogues, glucagon-containing dual agonists, antibody–peptide conjugates, biased agonists and AI-assisted discovery.

MariTide, zenagamtide (formerly amycretin) and ecnoglutide add further architectures to the monitoring list, but their exact status should always be checked against current sponsor and regulator records.

A practical development brief should define the exact molecular construct, intended use, development stage, target jurisdiction and legal product category before material is sourced or process work begins.

It should also identify critical quality attributes, reference standards, potency strategy, impurity risks, formulation requirements, scale assumptions, documentation needs and the owners of regulatory and intellectual-property review.

Clinical momentum can identify where the field is moving.

It does not remove the need for molecule-specific CMC evidence.